Palantir Faces Burry Critique And UK Scrutiny As Anthropic Competition Grows

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Investor Michael Burry publicly reiterates a short position in Palantir Technologies, criticizing NasdaqGS:PLTR's premium AI valuation and highlighting Anthropic as a lower cost competitor.

• Anthropic ramps up its own AI offerings, adding pressure to Palantir's claim to a premium position in enterprise and government AI software.

• UK regulators and ethics bodies increase scrutiny of Palantir's government and healthcare contracts, raising questions about data privacy and long term contract risk.

• These developments coincide with a sharp pullback in NasdaqGS:PLTR, which closed at $140.76 and remains very far above its level three years ago, alongside a 53.0% 1 year return.

For investors watching NasdaqGS:PLTR, the tension is now between a strong long term share price record and a sharper, more vocal bear case. The stock is down 3.9% over the past week, 10.0% over the past month, and 16.1% year to date, even after a 53.0% return over the past year and a very large gain over three years. That mix of strong trailing performance and recent pullback is now being reframed by critics who question how defensible Palantir's premium AI position really is.

Looking ahead, the key questions are likely to center on how Palantir responds to Anthropic's push into large scale AI tooling and how UK regulatory and ethical scrutiny shapes its government and healthcare pipeline. For you as an investor, the focus may be less on headline volatility and more on whether these pressures meaningfully change Palantir's contract profile, pricing power, and perceived moat over time.

Stay updated on the most important news stories for Palantir Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Palantir Technologies.

Is Palantir Technologies's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.

The latest criticism from Michael Burry and Anthropic's product push lands at a sensitive time for Palantir, because UK regulators and ethics groups are already questioning how its AI platforms are used in healthcare and defense. For you, the key issue is not only whether Anthropic, OpenAI, Microsoft or Google offer cheaper or more flexible AI tooling, but also whether UK scrutiny leads to tighter rules, extra approval steps, or contract specific restrictions around Palantir's NHS and government work. That kind of oversight can lengthen sales cycles, add compliance costs, or limit how data can be combined across agencies, which matters for a company that pitches itself as an operating system for sensitive data. At the same time, recently renewed deals with Stellantis, the expanded Bain & Company partnership and the Pentagon's Maven decision show that large institutions still choose Palantir for complex AI deployments, even as the public debate grows louder.